PCVX:NSD-Vaxcyte Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 81.86

Change

0.00 (0.00)%

Market Cap

USD 10.93B

Volume

1.06M

Analyst Target

USD 49.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-01 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+1.35 (+0.33%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+2.96 (+0.41%)

USD 84.94B
ARGX argenx NV ADR

+1.13 (+0.18%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

+0.66 (+0.28%)

USD 31.66B
BGNE BeiGene Ltd

N/A

USD 20.24B
UTHR United Therapeutics Corporatio..

-3.89 (-1.08%)

USD 16.18B
MRNA Moderna Inc

+0.18 (+0.43%)

USD 16.10B
RPRX Royalty Pharma Plc

+0.05 (+0.19%)

USD 15.05B
INCY Incyte Corporation

+0.10 (+0.14%)

USD 13.52B
SMMT Summit Therapeutics PLC

-0.11 (-0.60%)

USD 13.43B

ETFs Containing PCVX

W311:F HAN-GINS Indxx Healthcare.. 6.71 % 0.00 %

+0.11 (+13.62%)

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 6.71 % 0.00 %

+0.01 (+13.62%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 6.71 % 0.00 %

+0.13 (+13.62%)

N/A
MEDI Harbor Health Care ETF 6.14 % 0.00 %

+0.44 (+13.62%)

USD 0.02B
HVAX:CA 4.86 % 0.00 %

N/A

N/A
XRS2:SW Xtrackers Russell 2000 UC.. 0.48 % 0.00 %

+5.55 (+13.62%)

USD 2.22B
R2US:SW SPDR® Russell 2000 US Sm.. 0.39 % 0.00 %

+0.95 (+13.62%)

USD 4.99B
RSSL Global X Funds 0.39 % 0.00 %

+1.39 (+13.62%)

USD 1.48B
ITWO Proshares Russell 2000 Hi.. 0.35 % 0.00 %

+5.41 (+13.62%)

USD 0.05B
HDG ProShares Hedge Replicati.. 0.00 % 0.95 %

+0.13 (+13.62%)

USD 0.03B
IWM iShares Russell 2000 ETF 0.00 % 0.19 %

+3.29 (+13.62%)

N/A
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

+5.98 (+13.62%)

N/A
PTH Invesco DWA Healthcare Mo.. 0.00 % 0.60 %

+0.78 (+13.62%)

USD 0.12B
BTEC 0.00 % 0.42 %

N/A

N/A
VRTGX Vanguard Russell 2000 Gro.. 0.00 % 0.00 %

+8.28 (+13.62%)

USD 1.19B
VRTIX Vanguard Russell 2000 Ind.. 0.00 % 0.00 %

+5.66 (+13.62%)

USD 10.02B
SCHA Schwab U.S. Small-Cap ETF 0.00 % 0.05 %

+0.41 (+13.62%)

USD 18.38B
URTY ProShares UltraPro Russel.. 0.00 % 0.95 %

+2.15 (+13.62%)

USD 0.49B
UWM ProShares Ultra Russell20.. 0.00 % 0.95 %

+1.26 (+13.62%)

USD 0.50B
VTWG Vanguard Russell 2000 Gro.. 0.00 % 0.20 %

+4.00 (+13.62%)

USD 1.02B
VTWO Vanguard Russell 2000 Ind.. 0.00 % 0.15 %

+1.38 (+13.62%)

USD 12.28B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.17 (13.62%)

USD 5.18B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.02 (13.62%)

USD 5.15B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

-59.00 (13.62%)

USD 2.22B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

+0.35 (+13.62%)

USD 2.22B
R2US:PA SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

-0.23 (13.62%)

USD 5.17B
XRS2:F Xtrackers (IE) Public Lim.. 0.00 % 0.00 %

+4.60 (+13.62%)

USD 1.19B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.00 % 0.00 %

+0.92 (+13.62%)

USD 2.91B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.00 % 0.00 %

-1.25 (13.62%)

USD 1.19B
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.00 % 0.00 %

-0.17 (13.62%)

USD 2.91B
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.01 (+13.62%)

USD 0.02B
GERM 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 31.04% 79% B- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.04% 79% B- 79% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 38.97% 74% C 84% B
Dividend Return 38.97% 74% C 84% B
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 54.67% 60% D- 35% F
Risk Adjusted Return 71.29% 98% N/A 88% B+
Market Capitalization 10.93B 98% N/A 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector